Vir Biotech up 21% on coronavirus buying frenzy 
 Thinly traded Vir Biotechnology (VIR ) is up up on almost a 4x surge in volume, albeit a relatively modest 514K shares, as the animal spirits continue to sweep up companies that may be positioned to benefit from the coronavirus outbreak.

The company has four technology platforms that it is leveraging to develop treatments for infectious diseases, including influenza and tuberculosis.